Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42771   clinical trials with a EudraCT protocol, of which   7044   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-002879-17
    Sponsor's Protocol Code Number:20160370
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-05-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-002879-17
    A.3Full title of the trial
    A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
    Estudio de expansión abierto, multicéntrico y de fase 1b/2 para
    evaluar la seguridad y la eficacia de AMG 420 en monoterapia en sujetos con mieloma múltiple en recaída y/o refractario.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Safety and Efficacy of AMG 420 in Subjects with With Relapsed and/or Refractory Multiple Myeloma
    Estudio de la seguridad y la eficacia de AMG 420 en sujetos con mieloma múltiple en recaída y/o refractario
    A.4.1Sponsor's protocol code number20160370
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmgen Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmgen (EUROPE) GmbH
    B.5.2Functional name of contact pointMedinfoInternational@amgen.com
    B.5.3 Address:
    B.5.3.1Street AddressSuurstoffi 22, P.O. Box 94
    B.5.3.2Town/ cityRotkreuz
    B.5.3.3Post codeCH-6343
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+41413690300
    B.5.5Fax number+41413690400
    B.5.6E-mailMedinfoInternational@amgen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAMG420
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot available
    D.3.9.2Current sponsor codeAMG 420
    D.3.9.3Other descriptive name“bispecific T-cell engager” (BiTE®) antibody construct
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed or Refractory Multiple Myeloma
    Mieloma múltiple en recaída y/o refractario
    E.1.1.1Medical condition in easily understood language
    Bone marrow Cancer
    Cáncer de médula ósea
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10028228
    E.1.2Term Multiple myeloma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1b
    • Establish the safety and tolerability of AMG 420 at dose levels of 400 µg/day and 600 µg/day in subjects with relapsed and/or refractory multiple myeloma (RRMM).
    Phase 2
    • Estimate overall response rate (ORR) per IMWG response criteria (stringent complete response [sCR], complete response [CR], very good partial response [VGPR], partial response [PR]) in subjects with RRMM.
    Fase 1b
    • Establecer la seguridad y tolerabilidad de AMG 420 a unos niveles de dosis de 400 μg/día y 600 μg/día en sujetos con mieloma múltiple en recaída y/o refractario (MMRR).
    Fase 2
    • Estimar la TRG conforme a los criterios de respuesta del IMWG
    (respuesta completa estricta [RCe], respuesta completa [RC], respuesta parcial muy buena [RPMB], respuesta parcial [RP]) en sujetos con MMRR.
    E.2.2Secondary objectives of the trial
    Phase 1b
    Key Secondary
    • Estimate ORR and duration of response (DOR) of AMG 420 in subjects with RRMM
    • Evaluate the rate of minimal residual disease (MRD)-negativity at the time of CR
    Secondary
    • Establish the safety and tolerability of AMG 420 in subjects with extramedullary relapsed multiple myeloma
    •Characterize the pharmacokinetics of AMG 420 when administered as 4- week continuous intravenous (cIV) infusion
    •Evaluate other measures of anti-myeloma activity of AMG 420 in subjects with RRMM:
    −Time to response
    −Progression-free survival (PFS)
    −Overall survival (OS)
    −Treatment-free interval (TFI)
    −Best overall response (BOR)
    Phase 2
    Key Secondary
    • Estimate DOR of AMG 420 in subjects with RRMM
    • Evaluate the rate of MRD-negative disease at the time of CR
    Secondary
    • Evaluate other measures of anti-myeloma activity of AMG 420 in subjects with RRMM:
    −Time to response
    −PFS
    −OS
    −TFI
    −BOR
    • Establish the safety and tolerability of AMG 420 in subjects with RRMM
    Fase1b
    •Estimar la tasa de respuesta global y la duración de la respuesta deAMG420 en los sujetos conMMRR
    •Evaluar la tasa de enfermedad residual mínima(ERM)negativa en el momento de laRC
    Secundarios
    •Establecer la seguridad y tolerabilidad de AMG420 en sujetos con MM en recaída extramedular
    •Caracterizar la farmacocinética de AMG420 cuando se administra mediante perfusión intravenosa continua(IVc) durante 4 semanas
    •Evaluar otras medidas de actividad antimieloma deAMG420 en sujetos conMMRR:
    -Tiempo hasta la respuesta
    -Supervivencia libre de progresión(SLP)
    -Supervivencia global(SG)
    -Intervalo sin tratamiento(IST)
    -Mejor respuesta global(MRG)
    Fase2
    Secundarios clave
    •Estimar la DR deAMG420 en sujetos conMMRR
    •Evaluar la tasa de ERM negativa en el momento de la RC
    Secundarios
    •Evaluar otras medidas de actividad antimieloma deAMG420 en sujetos conMMRR:
    -Tiempo hasta la respuesta
    -SLP
    -SG
    -IST
    -MRG
    •Establecer la seguridad y tolerabilidad deAMG420 en sujetos conMMRR
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subject has provided informed consent prior to initiation of any study specific activities/procedures.
    Age ≥ 18 years at the time of the signing of informed consent.
    Multiple myeloma meeting the following criteria:
    •Pathologically-documented diagnosis of multiple myeloma that is relapsed or is refractory as defined by the following:
    −Relapsed after ≥ 3 lines of prior therapy that must include a PI, an IMiD, and a CD38-directed monoclonal antibody in any order during the course of treatment OR refractory to PI, IMiD, and CD38-directed monoclonal antibody.
    •Measurable disease, defined by 1 or more of the following at time of screening:
    −serum M-protein > 0.5 g/dL measured by serum protein electrophoresis (SPEP)
    −urinary M-protein excretion > 200 mg/24 hours
    −Involved sFLC measurement > 10 mg/dL, provided that the sFLC ratio is abnormal (< 0.26 or > 1.65) as per IMWG response criteria.
    Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
    Life expectancy of at least 3 months as per investigator`s judgment at time of screening.
    Hematological function without transfusion support (within 7 days from screening assessment) as follows:
    •ANC ≥ 1.0 x 109/L (without growth factor support)
    •platelet count ≥ 25 x 109/L (without transfusions)
    •hemoglobin ≥ 7.0 g/dL (transfusions permitted no later than 48 hours before screening).
    Renal function as follows:
    • calculated or measured creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation or via 24-hour urine collection with plasma and urine creatinine concentrations, respectively.
    Hepatic function as follows:
    •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
    • total bilirubin (TBIL) < 1.5 x ULN (unless considered due to Gilbert’s syndrome).
    El sujeto ha proporcionado su consentimiento informado antes de iniciar
    cualquier procedimiento/actividad específicos del estudio.
    Edad ≥ 18 años en el momento de firmar el consentimiento informado.
    Mieloma múltiple que cumple los criterios siguientes:
    •Diagnóstico documentado anatomopatológicamente de mieloma múltiple
    en recaída o refractario definido por lo siguiente:
    - Recaída después de ≥ 3 líneas previas de tratamiento, que deben incluir (en cualquier orden) un IP, un IMiD y un anticuerpo monoclonal dirigido contra CD38, durante el tratamiento, o enfermedad refractaria al tratamiento con IP, IMiD y anticuerpos monoclonales dirigidos contra CD38.
    •Enfermedad medible, definida por 1 o más de los criterios siguientes en el momento de la selección:
    - Proteína M en suero > 0,5 g/dl determinada mediante electroforesis de proteínas en suero (SPEP).
    - Excreción de proteína M en la orina > 200 mg/24 horas.
    - Determinación de la sFLC afectada > 10 mg/dl, siempre que la proporción de sFLC sea anormal (< 0,26 o > 1,65) según los criterios de respuesta del IMWG.
    Estado funcional ECOG (Eastern Cooperative Oncology Group) de ≤ 2.
    Esperanza de vida de al menos 3 meses, según el criterio del investigador, en el momento de la selección.
    La función hematológica siguiente, sin transfusión de apoyo (en los 7 días
    previos a la evaluación de la selección):
    •RAN ≥ 1,0 x 109/l (sin apoyo con factor de crecimiento).
    •Recuento plaquetario ≥ 25 x 109/l (sin transfusiones).
    •Hemoglobina ≥ 7,0 g/dl (se permiten transfusiones hasta 48 horas antes de la selección).
    La función renal siguiente:
    •Aclaramiento de creatinina ≥ 30 ml/min calculado con la ecuación de Cockcroft-Gault o medido mediante la recogida de una muestra de orina de 24 horas para determinar las concentraciones de creatinina en plasma y orina.
    La función hepática siguiente:
    •Aspartato aminotransferasa (AST) y alanina aminotransferasa (ALT) < 3 x límite superior de la normalidad (LSN).
    •Bilirrubina total (BiT) < 1,5 x LSN (salvo que se considere debida a síndrome de Gilbert).
    E.4Principal exclusion criteria
    Disease Related:
    Known central nervous system involvement by multiple myeloma.
    Evidence of primary or secondary plasma cell leukemia at the time of screening.
    Waldenstrom’s macroglobulinemia.
    Unresolved toxicities from prior anticancer therapy.
    Other Medical Conditions
    History of other malignancy within the past 3 years, with the following exceptions:
    •malignancy treated with curative intent and with no known active disease present for ≥ 1 year before enrollment and felt to be at low risk for recurrence by the treating physician
    •adequately-treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    •adequately-treated cervical carcinoma in situ without evidence of disease
    •breast ductal carcinoma in situ with full surgical resection (ie, negative margins) and without evidence of disease
    •prostate cancer with a Gleason score < 6 with undetectable prostate specific antigen (PSA) over 12 months
    •treated medullary or papillary thyroid cancer
    •adequately-treated urothelial papillary noninvasive carcinoma or carcinoma in situ
    •similar neoplastic conditions with an expectation of > 95% five-year disease-free survival
    • see exclusion criterion 202 (Evidence of primary or secondary plasma cell leukemia at the time of screening) for exclusion of subjects with evidence of primary or secondary plasma cell leukemia at the time of screening.
    Known history of amyloidosis.
    Current or known history of autoimmune diseases requiring systemic treatment in past 5 years except vitiligo, resolved childhood asthma/atopy, or subjects with history of hypothyroidism after completing treatment for autoimmune thyroid disease, stable on hormone replacement therapy.
    Clinically not-controlled chronic or ongoing infectious disease requiring treatment at the time of study day 1 or within the 14 days before study day 1
    Symptomatic peripheral sensory or motor neuropathy of grade ≥ 3.
    History or presence of clinically relevant central nervous system (CNS) pathology as uncontrolled epilepsy or seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson’s disease, cerebellar disease, organic brain syndrome, and psychosis.
    Active hepatitis B and C based on the following results:
    •Positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B).
    •Negative HepBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B.
    •Positive Hepatitis C virus antibody (HepCAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.
    Known or suspected HIV infection or subjects who are HIV seropositive.
    Baseline ECG QTc > 470 msec (applying Fridericia correction), defined as the average of individual baseline ECGs.
    Prior/Concomitant Therapy
    Previously received an allogeneic stem cell transplant and the occurrence of 1 or more of the following:
    •received the transplant within 6 months prior to study day 1
    •received immunosuppressive therapy within the last 3 months prior to study day 1
    •any active acute graft versus host disease (GvHD), grade 2 to 4, according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
    •any systemic therapy against GvHD within 2 weeks prior to start of investigational product treatment.
    Autologous stem cell transplantation < 90 days prior to study day 1.
    Treatment with systemic immune modulators including, but not limited to, nontopical systemic corticosteroids (unless the dose is ≤ 10 mg/day prednisone or equivalent), cyclosporine, and tacrolimus within 2 weeks before study day 1.
    Last anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2 weeks prior to study day 1.
    Last treatment with a therapeutic antibody less than 4 weeks prior to study day 1.
    Systemic radiation therapy within 28 days prior to study day 1. Focal radiotherapy within 14 days prior to study day 1.
    Major surgery defined as surgery requiring general anesthesia with endotracheal intubation within 28 days prior to study day 1, unless discussed with and eligibility approved by Amgen medical monitor.
    Prior treatment with any drug that specifically targets BCMA on tumor cells (eg, other bi-specific antibody constructs, antibody drug conjugates, or CAR T-cells, except for subjects who were previously treated with AMG 420 in this study and who are candidates for second-course treatment.
    Treatment with medications known to cause QTc interval prolongation within the washout periods unless approved by the Amgen medical monitor.
    Prior/Concurrent Clinical Study Experience
    Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies).
    Relacionados con la enferm.
    Afectación conocida del SNC el MM
    Evid. de leucemia de cél. asmáticas primaria o secund. en el momento de la selec.
    Macroglobulinemia de Waldenström
    Toxi. no resueltas derivadas de un trt. anticanceroso prev.
    Otras enferm.
    Antecedentes de otras neoplasias malignas en los últimos 3años con las excepciones siguientes:
    •Tumor maligno tratado con intención curativa y sin presencia de enferm. activa confirmada durante≥1año antes de la inclusión y que el médico responsable del trt. considere de bajo riesgo de recurrencia
    •Cáncer de piel no melanomatoso o lentigo maligno tratados adecuadamente sin evid. de enferm.
    •Carcinoma cervicouterino insitu tratado adecuad. in evid. de enferm.
    •Carcinoma ductal de la mama insitu con resección quirúrgica completa(márgenes negativos)y sin evid. de enferm.
    •Cáncer de próstata con puntuación de Gleason<6 con antígeno (Ag) específ. de la próstata(PSA)indetectable durante12meses
    •Cáncer papilar o medular de tiroides tratado
    •Carcinoma urotelial papilar no invasivo o carcinoma insitu tratados adecua.
    •Una enferm. neoplásica similar con una expectativa de supervivencia libre de enferm. durante5años>95%
    •Véase el criterio de exclus. 202 sobre la exclus. de sujetos con evid. de leucemia de cél.plasmáticas primaria o secund. en el momento de la selec.
    Antecedentes conocidos de amiloidosis
    Presencia o antecedentes de enferm. autoinmun. que precisaron trt. sistémico en los últimos 5años excepto vitiligo o asma/atopia resuelta en la infancia o sujetos con antecedentes de hipotiroidismo tras completar el trt. para una enferm. tiroidea autoinmun. que se hubiera mantenido estable con el trt. hormonal sustitutivo
    Enferm. infecciosa crónica o presente no controlada clínic. que precisa trt. el día1 del estudio o en los 14d prev. al día1 del estudio
    Neuropatía motora o sensorial periférica sintomática de grado≥3
    Antecedentes/presencia de una patología del SNC clínic. relevante como epilepsia o trast. epiléptico sin controlar paresia afasia ictus lesiones cerebrales graves demencia enferm. de Parkinson enferm. del cerebelo síndrome orgánico cerebral y psicosis
    HepatitisByC activas según los siguientes resultados:
    •+para el Ag de superficie de la hepB(HepBsAg)(indica hepB crónica o hepB aguda reciente)
    •- ara HepBsAg y + para anticuerpo (Ab) del núcleo de la hepB: debe determ. el ADN del virus de la hepB mediante la reacción en cadena de la polimerasa.El ADN del virus dela hepB detectable sugiere una hepB oculta
    •+ ara Ab del virus de la hepC: debe determ. el ARN del virus de la hepC mediante RCP. El ARN del virus de la hepC detectable sugiere una hepC crónica
    Se sabe o se sospecha que el sujeto está infect. por elVIH o sujetos seropositivos para elVIH
    ECGbasal con un intervalo QTc>470 ms(tras aplicar la corrección de Fridericia), determ. mediante el promedio de losECGbasales individuales
    Trt. prev./concomitante
    Haber recibido anteriormente un traspl. alogénico de cél. progenitoras y 1 o más de los siguientes casos:
    •Haber recibido el traspl. en los6meses anteriores al día1 del estudio
    •Haber recibido trt. con inmunosupr. en los3meses anteriores al día1 del estudio
    •Enferm. del injerto contra el huésped(EICH)activa aguda de grado2a4 según los criterios de Glucksberg, o EICH activa crónica que precisa trt. sistémico
    •Administración de cualquier trt. sistémico para laEICH en las 2semanas previas al inicio del trt. con el prod. en investig.
    Traspl. autólogo de cél. progenitoras<90d antes del día1 del estudio
    Trt. con inmunomoduladores sistémicos como corticosteroides sistémicos no tópicos (a no ser que la dosis sea≤10 mg/día de prednisona o equivalente), ciclosporina o tacrólimus, entre otros, en las 2semanas previas al día1 del estudio
    Último trt. anticanceroso recibido<2 semanas antes del día1 del estudio
    Último trt. con un Ab terapéutico recibido menos de 4semanas antes del día1 del estudio
    Radioterapia sistémica en los 28d anteriores al día1 del estudio.Radioterapia focal en los 14d anteriores al día1 del estudio
    Cirugía mayor: cualquier cirugía que precise anestesia general con intubación endotraqueal, en los 28d anteriores al día1 del estudio a no ser que se comente con el monitor médico de Amgen y se acuerde su elegibilidad
    Trt. Prev. con cualquier fármaco dirigido específicamente contra el BCMA de las cél. tumorales (p.ej otros constructos de Ab biespecíf. conjug. Ab-fármaco o cél.T-CAR excepto para los sujetos que recibieran trt. Prev. con AMG420 en este estudio y que sean candidatos a una segunda tanda de trt.
    Trt. con medicamentos que prolongan el intervalo QTc teniendo en cuenta los períodos de lavado a no ser que se obtenga la aprobación del monitor médico de Amgen
    Experiencia previa/concomitante en EC
    Estar recibiendo actualmente trt. en otro estudio de un fármaco o prod. sanitario en investig. o que hayan transcurrido menos de 30d desde el fin del trt. en otro estudio de un fármaco o prod. sanitario en investig.
    E.5 End points
    E.5.1Primary end point(s)
    Phase 1b
    • Dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, disease-related events, and changes in vital signs, electrocardiograms (ECGs), and clinical laboratory tests
    Phase 2
    • ORR according to IMWG response criteria, per IRC assessment
    Fase 1b
    • Toxicidades limitantes de la dosis (TLD), acontecimientos adversos queaparecen durante el tratamiento,
    acontecimientos adversos relacionados con el tratamiento, acontecimientos relacionados con la enfermedad y cambios en las constantes vitales, los electrocardiogramas (ECG) y las pruebas analíticas clínicas
    Fase 2
    • TRG conforme a los criterios de respuesta del IMWG, evaluados por el CRI
    E.5.1.1Timepoint(s) of evaluation of this end point
    Throughout study
    Durante el estudio
    E.5.2Secondary end point(s)
    Phase 1b
    Key secondary
    •ORR
    •DOR
    •MRD negativity at the time of CR
    Secondary
    •DLTs, treatment-emergent adverse events, treatment-related adverse events, disease-related events, and changes in vital signs, ECGs, and clinical laboratory tests
    •AMG 420 PK parameters including, but not limited to, half-life (t1/2), clearance, and apparent Css
    • Efficacy parameters according to International Myeloma Working Group (IMWG) response criteria, per independent review committee (IRC) assessment:
    −Time to response
    −PFS
    −BOR
    •OS
    •TFI
    Phase 2
    Key secondary
    • DOR
    • MRD negativity at the time of CR
    Secondary
    •Efficacy parameters according to IMWG
    response criteria, per IRC assessment:
    −Time to response
    −PFS
    −BOR
    •OS
    •TFI
    • Treatment-emergent adverse events, treatment-related adverse events, disease-related events, and changes in vital signs, ECGs, and clinical laboratory tests
    Fase 1b
    Secundarios clave
    •TRG
    •DR
    •ERM negativa en el momento de la RC
    Secundarios
    •TLD, acontecimientos adversos que aparecen durante el tratamiento, acontecimientos adversos relacionados con el tratamiento, acontecimientos relacionados con la enfermedad y cambios en las constantes vitales, los ECG y las
    pruebas analíticas clínicas
    •Parámetros FC de AMG 420, como la semivida (t1/2), el aclaramiento y la Css aparente
    •Parámetros de eficacia de acuerdo con los criterios de respuesta del International Myeloma Working Group (IMWG), evaluados por el comité de revisión independiente (CRI):
    - Tiempo hasta la respuesta
    - SLP
    - MRG
    •SG
    •IST
    Fase 2
    Secundarios clave
    •DR
    •ERM negativa en el momento de la RC
    Secundarios
    •Parámetros de eficacia conforme a los criterios de respuesta del IMWG, evaluados por el CRI:
    - Tiempo hasta la respuesta
    - SLP
    - MRG
    •SG
    •IST
    •Acontecimientos adversos que aparecen durante el tratamiento,acontecimientos adversos
    relacionados con el tratamiento, acontecimientos relacionados con la enfermedad y cambios en las constantes vitales, los ECG y las pruebas analíticas clínicas
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout study
    Durante el estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1b: dose confirmation
    Fase 1b: confirmación de dosis
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA32
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Austria
    Belgium
    Canada
    France
    Germany
    Italy
    Japan
    Romania
    Spain
    Switzerland
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 40
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 80
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state7
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-06-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-06-14
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA